INT289988

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.02
First Reported 2008
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 4
Disease Relevance 3.35
Pain Relevance 0.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Narf)
Narf (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 44 97.16 Very High Very High Very High
Onset of action 12 87.28 High High
headache 8 82.32 Quite High
Clonidine 16 78.16 Quite High
antagonist 24 26.32 Quite Low
Glutamate 32 5.00 Very Low Very Low Very Low
Inflammation 12 5.00 Very Low Very Low Very Low
beta blocker 8 5.00 Very Low Very Low Very Low
nMDA receptor 8 5.00 Very Low Very Low Very Low
cytokine 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Ocular Hypertension 360 100.00 Very High Very High Very High
Hypotension 36 99.52 Very High Very High Very High
Conjunctivitis 12 84.80 Quite High
Headache 8 82.32 Quite High
Hypersensitivity 20 81.20 Quite High
Glaucoma 320 72.00 Quite High
Anxiety Disorder 4 64.72 Quite High
Hypertension 8 64.20 Quite High
Heart Rate Under Development 16 63.36 Quite High
Age-related Macular Degeneration 12 62.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In clinical studies, travaprost once daily produced reductions in IOP of between 7-8 mmHg, from a mean baseline IOP of 25-27 mmHg, an effect similar to that noted in the case of bimatoprost or latanoprost.[79] In controlled clinical trials, travaprost 0.004% once daily, used as monotherapy, produced greater IOP reduction than timolol 0.5% b.i.d and equal or greater reduction than latanoprost 0.005%.[80]
Gene_expression (produced) of IOP associated with ocular hypertension
1) Confidence 0.02 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792620 Disease Relevance 0.78 Pain Relevance 0.09
It produces 20-24% reduction in IOP.
Gene_expression (produces) of IOP associated with ocular hypertension
2) Confidence 0.02 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792620 Disease Relevance 1.06 Pain Relevance 0.48
The addition of latanoprost to timolol treatment produces an additional IOP reduction of 13-37%, depending upon the frequency of the application and the baseline IOP.
Gene_expression (produces) of IOP associated with ocular hypertension
3) Confidence 0.02 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792620 Disease Relevance 0.77 Pain Relevance 0
In clinical studies, travaprost once daily produced reductions in IOP of between 7-8 mmHg, from a mean baseline IOP of 25-27 mmHg, an effect similar to that noted in the case of bimatoprost or latanoprost.[79] In controlled clinical trials, travaprost 0.004% once daily, used as monotherapy, produced greater IOP reduction than timolol 0.5% b.i.d and equal or greater reduction than latanoprost 0.005%.[80]
Gene_expression (produced) of IOP associated with ocular hypertension
4) Confidence 0.02 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792620 Disease Relevance 0.74 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox